Liftstream is an executive search recruitment company in the life sciences sector
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
Posted in Orphan Drugs and Rare Diseases
Tagged AbbVie, Actelion, Alexion, bioValley, Boston, Boston Biotech, Flemming Ornskov, M&A, NPS Pharmaceuticals, Orphan Drug, Pfizer, Rare Disease, Shire, SOBI, Swiss, Synageva
Leave a comment
Novimmune sees immunotherapy and orphan focus attract new capital
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged acute lymphocytic leukemia, Alexion, Angel investment, Ariad, bioValley, Covagen, Crohn's disease, Dr Jonathan hepple, Geneva, Hemophagocytic lymphohistiocytosis, Lomard odier ventures, Merck Serono, monoclonoal antibody therapeutics, NovImmune, Nyon, Rare Disease, renal allograft transplantation, Rosetta Capital, Shire, Switzerland, Vertex Pharmaceuticals, Zug
Leave a comment
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Aegerion, Alexion, Amgen, BioMarin, Bloomberg, Breakthrough Therapy, Catalyst Pharmaceutical Partners, Chiesi, Chiesi Farmaceutici, EMA, FDA, Flemming Ornskov, Human Genetic Therapies, Jean-Jacques Bienaimé, Kamada, Kyprolis, life sciences, lysosomal storage diseases, M&A, Nexavar, NPS Pharmaceuticals, Onyx, Orphan drugs, pharmaceutical industry, rare diseases, regenerative medicine, Roche, San Francisco, Sarepta, Shire, speciality pharma, Ugo di Francesco, uniQure, Zymenex
Leave a comment
Omeros into phase 1 clinical trial in Europe
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged aHUS, Alexion, clinical development, Gregory Demopulos, mannan-binding lectin-associated serine protease-2, MASP-2, Omeros Corporation, Omeros Pharma, OMS721, Phase II, Soliris, thrombotic microangiopathy, uremic syndrome, US Biotech
Leave a comment
Rare Disease Year in Review
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events:
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Actelion, Alexion, BioMarin, BlubirdBio, Chiesi, Elelyso, Emil Kakkis, Enobia, Forbes, Genzyme, IPO, Lysogene, M&A, Prosensa, Protalix, rare diseases, regulatory affairs, regulatory approval, Replagal, Sanofi, Shire, Soliris, Supernus Pharmaceuticals, ultra-rare diseases, Ultragenyx, uniQure, VPRIV
Leave a comment